Intrance Medical Systems

Intrance Medical Systems is a clinical-stage biotech company targeting a significant unmet need in advanced Parkinson's disease (APD) with its lead product, a continuous intestinal infusion therapy. The product, known as Lecigon® in Europe, combines a proprietary drug gel with a lightweight pump, aiming to provide more stable symptom control than oral medications. Founded in 2015 and based in San Diego, the company is leveraging European regulatory approval and real-world experience to advance its U.S. clinical program, supported by a $17 million Series A financing and a leadership team with deep experience in Parkinson's disease and drug-device combinations.

Proprietary drug-device combination platform featuring a fixed-dose gel of levodopa/carbidopa/entacapone and a wearable infusion pump for continuous intestinal delivery.

Intrance competes in the device-assisted therapy segment for advanced PD, directly against AbbVie's Duopa® (levodopa/carbidopa intestinal gel) and deep brain stimulation systems. Its product differentiates by including entacapone in a fixed-dose combination gel. Broader competition includes subcutaneous apomorphine infusion and emerging oral therapies.